Boston-based Moderna has been the S&P 500’s most shorted stock since the end of September, according to S3 Partners. Short ...

President Trump is expected to unveil plans to lower healthcare costs, which could significantly impact the pharmaceutical industry. Additionally, Pfizer's (PFE) entry into the weight-loss drug space, ...

Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

Moderna ($MRNA) steps into Thursday’s analyst day with more pressure than momentum. The stock is down more than 40% this year ...

Moderna’s stock has seen a notable shift in sentiment after its fair value estimate was cut from $40.30 to $37.32. This ...

Moderna (NASDAQ:MRNA) gained 3% on Thursday after presenting a new multi-year roadmap at its Analyst Day, detailing how it ...

The biotechnology firm announced it aims to achieve up to 10% revenue growth in 2026 while working toward cash breakeven by 2028. Moderna plans to expand its seasonal vaccine franchise from three to ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. This might not be enough to turn around the fortunes of the developer of go-to COVID-19 ...

Moderna Inc.’s stock reached a 52-week low, closing at 23.04 USD, reflecting a significant downturn over the past year. The biotech company’s shares have experienced a substantial decline, with a year ...

In this week's STATus Report, STAT reporters Jason Mast and Damian Garde discuss the challenges facing Moderna — and what could be in store for its third act.

Shares of Moderna are falling Thursday. The company made two significant announcements regarding its finances and business ...